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Metastatic melanoma and pregnancy
Borislava L. Nikolin, Olivera 'veljo
ABSTRACT
Pregnancy after complete treatment of metastatic melanoma is an extremely rare event. We presented
a case of a skin melanoma patient with lung and liver metastases who was treated by combined
immunochemotherapy for the period of two years. A year and a half after the successful treatment, which
resulted a complete remission of metastatic lesions she got pregnant and delivered a healthy baby girl.
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INTRODUCTION 
C
utaneous melanoma is known to have the capacity to metastasize to virtually any organ.
Most frequent are metastatic lesions in liver (54%) and lung (58%). Metastatic
melanoma has very limited responsiveness to chemo- or immunotherapy (1). Response
rate is less than 20%, and the median overall survival for stage IV is 4 to 12 months
(depending on invaded organs). Combined immunochemotherapy has showed some activ-
ity in metastatic melanoma, but it has not been possible yet to define standard therapy,
which should be the most beneficial. The rationale for combining cytostatics with interfer-
on for treatment of melanoma is based on the assumption of their different antitumor mech-
anisms (2-4).
The estimated incidence of melanoma complicating pregnancy ranged from 0.1 to 2.8 per
1,000 pregnancies, although data from this population have not been systematically ascer-
tained (4). Despite the fact that melanoma is not the most common cancer in pregnancy, it
is most likely that it will metastasize to the placenta and fetus. Melanoma incidence rates
are increasing dramatically, and melanoma is now a major cause of cancer death in women
of childbearing age. To facilitate appropriate patient education, clinical and histologic eval-
uation, physicians should be familiar with the data regarding fetal complications in a preg-
nant woman with melanoma. Most published discussions regarding management and treat-
ment of metastatic melanoma in pregnancy have focused on the mother, with no analysis
of fetal management published to date (5).
Pathologists should carefully examine the placentas of women with known or suspected
metastatic melanoma, grossly and histologically. With placental involvement, fetal risk of
melanoma metastasis is approximately 22%. Neonates delivered with concomitant placen-
tal involvement should be considered a high-risk population. The risk-benefit ratio of adju-
vant treatment for a potentially affected infant should be carefully weighed.
Placental involvement of maternal cancer has been defined as gross or microscopic evi-
dence of maternal cancer within any section of the placenta. Fetal metastasis has been
defined as metastasis of maternal cancer developing in the fetus, with no evidence of pri-
mary tumor originating in the fetus. Since the first case report in 1866, only 87 patient cases
of placental or fetal metastasis have been reported. It is important to note that the number
of patient cases reported in the literature is increasing, with more than 20% of the patient
cases being reported in the last decade (6,7).
CASE PRESENTATION
A 38-year-old woman was admitted to the Institute of Oncology in January 2001; after rou-
tine check up she was completely asymptomatic but standard radiography of chest showed
suspicious infiltration on right side of lung and ultrasound of liver showed metastasis in right
lobe. She had Karnofsky performance of 100.
Her medical history showed pigmented skin lesion of right arm, which was radically excised
on February 14, 1997. The histopathological examination disclosed a superficial spreading
melanoma, measuring 3.2mm of thickness (Breslow V), Clark invasion II. She was classi-
fied in stage II A (UICC/AJCC) of melanoma and regularly followed up till January 2001.
Visceral evaluation by CT scan showed bilateral multiple metastases of lung (from 2.5cm
to 0.5cm) and revealed two metastases in right lobe of liver (approximate diameter 4cm)
(Figure 1). 
The laboratorial exams were within normal ranges. After the disease progression (stage IV),
the patient was submitted to immunochemotherapy. She received 12 cycles of combined
chemotherapy: dacarbazine (250mg/m† IV, day 1-3)+cisplatin (25mg/m† IV, day 1-3)
every 4 weeks + interferon alpha (6 MU, SC, 3x weekly, in TD 180 MU, and 3 MU, SC, 3x
weekly, in TD 180 MU). First complete evaluation by CT scan was performed after four
cycles of chemotherapy, and showed partial regression of all metastatic lesions. We decid-
ed to continue with same therapy, which resulted in further regression of metastatic lesions,
what was confirmed by CT scan (Figure 2).
Concerning toxic and side effects (leukopenia, polineuropathy, nausea, vomiting, gastritis,
hypertension, headache, mild flu like symptoms) as well as excellent result of therapy, we
continued with single agent therapy with dacarbazine (four cycles more). As complete
remission was achieved in June 2002 we continue with frequent checkups. Last CT scan
was done in May 2003 and confirmed complete remission (Figure 3).
Planning maternity, in spite of all warnings for possible complications either her or
fetus/infant, she got pregnant in December 2003. In the course of pregnancy all examina-
tions that are available in our country were performed regularly. Delivery was normal, ontime-gestational age of 36 weeks (in August 2004), microscopic placental examination
gave normal histopathological findings and baby girl was Apgar score 9. Her last checkup
(laboratory findings, radiography of lung, ultrasound of liver) in October 2004 showed nor-
mal results.
DISCUSSION
Melanoma is the cancer most commonly found to involve the placenta and fetus, account-
ing for 27 of 87 (31%) patient cases published to date. Advances in cytogenetic tumor
analysis using cellular DNA markers that permit discrimination between maternal and fetal
cells now make it possible to establish the maternal origin of the tumor more conclusively.
The most common sites of presentation included the liver and subcutaneous tissue (8,9).
During the period from 1918 to 2002, there were 27 patients with melanoma reported to
involve the placenta or fetus. Microscopic evaluation was performed in 24 of 27 patients,
and placental involvement was documented in all 24 patients. Six of the 27 reports indicat-
ed fetal metastasis, but three reports did not document corresponding placental involve-
ment.
Previously published reviews focused on assessing the risk of maternal-fetal transmission
of melanoma and calculated an approximate 25% mortality risk to babies born to mothers
with placental involvement. Infants developing clinical evidence of maternally derived
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Figure 1. Patient s CT findings before therapy 2001. Lung metastases are clearly evident in both lung and mediastinal window )arrows) as well as
Figure 2. CT findings after one year of immunochemotherapy (2002) - an almost complete response of lung and liver metastasis
Figure 3. CT scans of the same patient after two years (year 2003) showing complete remission of lung and liver metastasismetastases have an exceptionally poor prognosis, with death typically occurring within 3
months of diagnosis. Thus, neonates delivered with concomitant placental involvement but
without clinical evidence of disease should be considered a high-risk population. Adjuvant
treatment of infants born to women with placental metastasis of melanoma has not been
reported (10,11).
In the past, physicians were only alerted to the occurrence of transplacental metastasis
when gross placental involvement or clinically evident fetal metastases were present.
Even when examined microscopically, metastatic deposits within the placenta may be dif-
ficult to localize, given its enormous blood supply. Multiple placental sections may be nec-
essary to document the true extent of placental invasion. Fetal metastasis requires two
components: maternal tumor invasion of fetal tissues and fetal inability to eliminate
metastatic cells. Placental or fetal vessel invasion may be necessary, but not sufficient, for
fetal metastasis.
Other maternal factors that have been reported to indicate an unfavorable fetal or infant out-
come include maternal age less than 30 years, primiparity, disease onset more than 3 years
before current pregnancy, nodal metastasis before pregnancy, more than three sites of
metastatic foci during the third trimester, primary site of the leg, and maternal death within
1 month of birth. However, data from the literature do not support any of these factors
(12,13).
Previously reported fetal factors indicating an unfavorable fetal or infant outcome include
birth at greater than 36 weeks and male sex. Gestational age at birth did not seem to influ-
ence risk of fetal transmission of melanoma. However, male infants seem to be at higher
risk than females for developing metastasis of any maternal cancer. Males comprised 80%
of all infants with metastasis of melanoma and 75% with metastasis of all cancers. Although
long-term survival cannot be determined for patients for whom follow-up was limited, the
only infant to survive without therapy was female, indicating that sex may influence survival.
The tendency of melanoma to metastasize to the fetus relative to other tumor types is
intriguing, but poorly understood. As part of the metastatic model recently proposed by
Hanahan and Weinberg, it is clear that metastatic cells must alter their expression of numer-
ous genes, including proteases, cellular adhesion molecules, and integrins before they are
able to invade and establish themselves in an alternative tissue environment. Because
melanoma is overrepresented in the number of placental metastases that occur during preg-
nancy, there must be some unique or dominant feature within melanoma cells relative to
other malignancies that allows this process to occur. An additional consideration is the fact
that the placenta is a site of production for many growth factors and is exceptionally vas-
cular. In fact, angiogenic factors produced by the placenta, including placental growth fac-
tor, hepatocyte growth factor, and vascular endothelial growth factor, have also been shown
to be released by, and to influence the growth of, melanoma cells in culture. It is also pos-
sible that placental growth factors or shared endothelial adhesion molecules encourage
adhesion, survival, and invasion of melanoma cells. This relative affinity of melanoma for
placental metastasis, growth, and invasion may account for the increased risk of fetal
metastasis (14-16).
An inadequate fetal immune response has also been suspected in the pathophysiology of
transplacental spread. In infants who present with metastases, immunologic tolerance
seems to have been induced. Tolerance may be induced by exposure to tumor antigens at
a time when the developing immune system is not yet capable of responding. T- and B-cell
responses in the fetus are thought to develop around weeks 7 to 10 and 14 to 20, respec-
tively, and many of the incidences of fetal metastasis occurred in women who had metasta-
tic disease before that date. Thus, metastatic cells may localize to the fetus early enough to
be considered self by the developing immune system. However, the timing of maternal
metastasis of melanoma does not seem to differ in placental versus fetal metastasis
(17,18).
The ability of the fetus to clear maternal metastatic cells seems to play a role in melanoma
as well. Given the risk of metastasis to the fetus, it is recommended that the placentas of
all women with suspected metastatic melanoma during pregnancy should be closely eval-
uated by gross and microscopic examination. Immunohistochemical staining for melanoma
antigens should be performed on histological sections, using S-100, HMB-45, or other
appropriate markers. Research tests that may be of value include examination of cord blood
buffy coat for the presence of tumor cells using immunohistochemical staining or reverse
transcriptase polymerase chain reaction. Research evaluation to establish the maternal ori-
gin of the tumor (including karyotyping, cytogenetics, and HLA typing of the mother, infant,
and tumors) may also be useful (19,20).
If the neonate does not present with metastases at birth, recommendation is periodic eval-
uation for development of melanoma for at least 24 months postpartum coinciding with rou-
tine well-child checks. Evaluation should include a baseline chest x-ray and liver enzymes,
including lactate dehydrogenase, which may be repeated every 6 months. Other studies
may be included on the basis of clinical suspicion.
Because of its rarity, studies regarding melanoma treatment are lacking in infants. At this
point, there is insufficient information to make a definitive recommendation about adjuvant
therapy for infants at risk for maternal melanoma metastases (21, 22).
CONCLUSION
Morbidity for the fetus in patients with placental disease is unclear. Pregnant women with
metastatic melanoma often had complicated clinical courses, but infants without fetal
metastasis did well. Prematurity is a common complication of infants born with placental
metastasis of melanoma, with a mean gestational age of 34 weeks, but the mortality rate
secondary to prematurity was low. Follow-up should be long-term. Because congenital and
infantile melanomas are so rare, there are no existing standardized guidelines for observa-
tion or therapy. Recommendations for follow-up include skin inspection, abdominal ultra-
sound, and screening for melanogens in the infant’s urine.
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